BioSpace News Archive

Brukinsa was approved for MSL patients who have received at least one anti-CD20-based regimen.

Data coming in about the COVID-19 pandemic shows some promising overall trends, with other more disturbing ones, particularly in breakthrough infections of the fully vaccinated.

Life sciences companies reeled in millions of dollars in Series C financing rounds this week. Here is a look at a few of those companies and what their fresh funds will be used for.

FDA has been actively greenlighting a number of efforts over the last few days to push therapies for rare or serious diseases that have largely unmet medical needs. Here’s a look.

All results are reported under International Financial Reporting Standards (“IFRS”) and in Canadian dollars, unless otherwise specified.

RwHealth, which provides AI solutions to NHS trusts appoints finnCap to facilitate listing.

Albert Einstein College of Medicine has received a five-year, $5 million grant from the National Institutes of Health to support the Rose F. Kennedy Intellectual and Developmental Disabilities Research Center, which has been at the forefront of research on normal and abnormal brain development for more than 50 years.

MedX Health Corp. (TSXV: MDX) (“MedX” or the “Company”), a global leader in teledermatology, is pleased to announce its participation in the Life Sciences Investor Forum, taking place virtually on Thursday, September 16 at 1:00 PM EST.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today announced that management will present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit and participate in a fireside chat at the Cantor Global Healthcare Conference.

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the publication of a profile of the company’s ETX0462 candidate in the prestigious scientific journal Nature (DOI: 10.1038/s41586-021-03899-0).